Abstracts tagged "Adalimumab"

Abstract Number: 576 • 2018 ACR/ARHP Annual Meeting
An Analysis of Early Introduction of Adalimumab and Subsequent Bio-Free Condition in the Patients with Rheumatoid Arthritis
Satoshi Ito¹, Yoichi Kurossawa^1,2, Eriko Hasegawa^1,2, Daisuke Kobayashi^1,2, Shinji Taniguhi¹, Asami Abe¹, Hiroshi Otani¹, Kiyoshi Nakazono¹, Akira Murasawa¹, Ichiei Narita² and Hajime Ishikawa¹, ¹Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Background/Purpose: HOPEFUL-1 trial showed efficacy of combination therapy with adalimumab (ADA) plus methotrexate (MTX) in MTX naïve patients with active early rheumatoid arthritis (eRA). In…
Abstract Number: 2270 • 2018 ACR/ARHP Annual Meeting
Treatment of Refractory Cystoid Macular Edema to Conventional Immunosuppressive Therapy: Tocilizumab Vs Anti-TNF-Alpha. Multicenter Study of 59 Patients
José Luis Martín-Varillas¹, Belén Atienza-Mateo¹, Vanesa Calvo-Río², Monica Calderón Goercke², Diana Prieto Peña², Rosalía Demetrio-Pablo³, Javier Loricera³, Eva Peña Sainz-Pardo³, M. Victoria Hernández⁴, Alfredo Adan⁵, Marina Mesquida⁵, Santos Insua⁶, Jose M Herreras⁷, Olga Maíz⁸, Ana Blanco⁹, Myriam Gandía¹⁰, David Diaz-Valle¹¹, Lucía Martínez-Costa¹², Elia Valls-Pascual¹², Gisela Díaz-Cordovés¹³, Manuel Díaz-Llopis¹⁴, Inmaculada Calvo¹⁵, Ignacio Torre-Salaberri¹⁶, Antonio Atanes¹⁷, Luis Francisco Linares¹⁸, Marisa Hernández¹⁹, Emma Beltrán²⁰, Miguel Cordero-Coma²¹, Elena Aurrecoechea²², Félix Francisco²³, Raquel Almodóvar González²⁴, Oscar Ruiz Moreno²⁵, Fernando Jiménez-Zorzo²⁶, Joan Miquel Nolla²⁷, Consuelo Modesto²⁸, Enar Pons¹, Miguel Angel González-Gay³ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁶Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, ⁷Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, ⁸Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, ⁹Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, ¹⁰Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, ¹¹Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ¹²Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ¹³Rheumatology, Hospital Regional Universitario de Málaga. Spain, Málaga, Spain, ¹⁴Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹⁵Hospital Universitario La Fe, Valencia, Spain, ¹⁶Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ¹⁷Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, ¹⁸Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ¹⁹Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ²⁰Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, ²¹Ophthalmology, Hospital de León. Spain, León, Spain, ²²Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, ²³Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ²⁴Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, ²⁵Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²⁶Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²⁷Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁸Hospital Universitari Vall d'Hebron. Barcelona. Spain, Barcenola, Spain
Background/Purpose: Cystoid macular edema (CME) is the main cause of irreversible visual loss in patients with uveitis. Our aim objective was to determine the efficacy…
Abstract Number: 2621 • 2018 ACR/ARHP Annual Meeting
Predictors of Survival of Adalimumab Treatment in the Management of Ankylosing Spondylitis and Psoriatic Arthritis in Canadian Routine Care
Louis Bessette^1,2, Majed Khraishi³, Jacqueline Stewart^4,5, Andrew Chow^6,7, Viktoria Pavlova⁸, Brandusa Florica^6,9 and Valencia P. Remple^10,11, ¹Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ²Rheumatology, Laval University, Quebec, QC, Canada, ³Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Penticton Regional Hospital, Penticton, BC, Canada, ⁵University of British Columbia, Penticton, BC, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Trillium Health Partners Credit Valley Hospital, Mississauga, ON, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Trillium Health Partners, Mississauga, ON, Canada, ¹⁰AbbVie Corporation, Montreal, QC, Canada, ¹¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Biologics therapy survival is often used as a proxy for treatment effectiveness and safety. However, it may be influenced by patient characteristics, utilization patterns,…
Abstract Number: 612 • 2018 ACR/ARHP Annual Meeting
Anti-Drug Antibodies Detected By Competitive ELISA Can Predict Treatment Failure in Patients Taking Adalimumab
Manca Ogrič¹, Polona Žigon¹, Katja Lakota^1,2, Sonja Praprotnik¹, David Drobne^3,4, Borut Štabuc^3,4, Snezna Sodin Semrl^1,2 and Saša Čučnik^1,5, ¹University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia, ²University of Primorska, Faculty of Mathematics, Natural Science and Information Technology, Koper, Slovenia, ³University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia, ⁴University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, ⁵University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia
Background/Purpose: A reduced clinical response in patients taking TNF-alpha inhibitors is influenced by their immunogenicity and therefore the importance of therapeutic drug monitoring has been…
Abstract Number: 2380 • 2018 ACR/ARHP Annual Meeting
The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry
Hermine I. Brunner¹, Nicola Ruperto², Kabita Nanda³, Mary Toth⁴, Ivan Foeldvari⁵, John F. Bohnsack⁶, Diana Milojevic⁷, Daniel J Kingsbury⁸, Katherine A. Marzan⁹, Elizabeth Chalom¹⁰, Gerd Horneff¹¹, Rolf M. Kuester¹², Jason A Dare¹³, Maria Trachana¹⁴, Mareike Bereswill¹⁵, Hartmut Kupper¹⁵, Daniel J Lovell¹⁶ and Alberto Martini², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Gaslini Institute and Pediatric Rheumatology International Trials Organisation, Genoa, Italy, ³Seattle Children's Hospital, Seattle, WA, ⁴Nemours Children’s Hospital, Orlando, FL, ⁵Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ⁶University of Utah, Salt Lake City, UT, ⁷Johns Hopkins All Children’s Hospital, St. Petersburg, FL, ⁸Randall Children’s Hospital, Portland, OR, ⁹Children's Hospital Los Angeles, Los Angeles, CA, ¹⁰The Pediatric Specialty Center at Saint Barnabas, West Orange, NJ, ¹¹Asklepios Children's Clinic, Sankt Augustin, Germany, ¹²Orthopädiezentrum Altona, Hamburg, Germany, ¹³Arkansas Children’s Hospital, Little Rock, AR, ¹⁴Hippokration General Hospital, Aristotle University, Thessaloniki, Greece, ¹⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁶PRCSG, Cincinnati Children’s Hospital Medical Center, Cinncinnati, OH
Background/Purpose: Adalimumab (ADA) has been approved for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) with long-term use often required to maintain disease control. The…
Abstract Number: 2825 • 2018 ACR/ARHP Annual Meeting
Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab
Ana Martínez^1,2, Chamaida Plasencia^2,3, Victoria Navarro-Compán², Borja Hernández-Breijo², Dora Pascual-Salcedo², Pilar Nozal⁴, Cristina Diego⁴, Irene Monjo^2,3, Laura Nuño^3,5 and Alejandro Balsa^2,6, ¹Immunology. La Paz University Hospital, Madrid, Spain, ²Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴La Paz University Hospital, Immunology, Madrid, Spain, ⁵Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Rituximab (Rtx) induces transient depletion of B cells. Previous data showed that Rtx is particularly effective on autoimmune diseases in which auto-antibodies (auto-Ab) are…
Abstract Number: 693 • 2018 ACR/ARHP Annual Meeting
Combining Adalimumab with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®
Omar Benryane¹, Louis Coupal² and Denis Choquette², ¹Médecine, Faculté de Médecine de l’Université de Montréal, Montréal, QC, Canada, ²Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: Psoriatic Arthritis (PsA) in a musculoskeletal inflammatory condition associated with psoriasis. It has a heterogeneous set of clinical manifestations which include peripheral arthritis, axial…
Abstract Number: 2381 • 2018 ACR/ARHP Annual Meeting
Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years
Daniel J Lovell¹, Nicola Ruperto², Andreas Reiff³, Lawrence Jung⁴, Katerina Jarosova⁵, Richard Mouy⁶, Isabelle Koné-Paut⁷, Olcay Y. Jones⁸, Veronika Vargova⁹, Carine Wouters¹⁰, Ivan Lagunes Galindo¹¹, Carmen Mak¹², Hermine I. Brunner¹³ and Alberto Martini², ¹Cincinnati Children’s Medical Center and Pediatric Rheumatology Collaborative Study Group Coordinating Center, Cincinnati, OH, ²Gaslini Institute and Pediatric Rheumatology International Trials Organisation, Genoa, Italy, ³Children's Hospital Los Angeles, Los Angeles, CA, ⁴Children’s National Health Systems, Washington, DC, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶Hôpital Necker-Enfants Malades, Paris, France, ⁷Bicetre Hospital, APHP, University of Paris Sud, Paris, France, ⁸Walter Reed National Military Medical Center, Bethesda, MD, ⁹Faculty Hospital, Kosice, Slovakia, ¹⁰University Hospital Gasthuisberg, Leuven, Belgium, ¹¹AbbVie Inc., North Chicago, IL, ¹²AbbVie, North Chicago, IL, ¹³Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a broad term that describes a clinically heterogeneous group of arthritides of unknown cause, which begin before 16 years…
Abstract Number: 890 • 2018 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
Roy Fleischmann¹, Aileen L. Pangan², Eduardo Mysler³, Louis Bessette⁴, Charles Peterfy⁵, Patrick Durez⁶, Andrew Ostor⁷, Yihan Li², Yijie Zhou², Ahmed A. Othman², In-Ho Song⁸ and Mark C. Genovese⁹, ¹University of Texas Southwestern Medical Center at Dallas, Metroplex Clinical Research Center, Dallas, TX, ²AbbVie, Inc., North Chicago, IL, ³Organización Medica de Investigación, Buenos Aires, Argentina, ⁴Laval University, Québec, QC, Canada, ⁵Spire Sciences LLC, Boca Raton, FL, ⁶Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁷Cabrini Medical Center, Malvern, Australia, ⁸AbbVie, Inc., north chicago, IL, ⁹Stanford University Medical Center, Palo Alto, CA
Background/Purpose: To assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib (UPA), a JAK1- selective inhibitor, vs placebo (PBO) and active comparator, originator…
Abstract Number: 2382 • 2018 ACR/ARHP Annual Meeting
Real-World Safety and Effectiveness of Adalimumab in Patients with Juvenile Idiopathic Arthritis: Results from a Post-Marketing Surveillance in Japan
Syuji Takei¹, Naomi Iwata², Ichiro Kobayashi^3,4, Toru Igarashi⁵, Yoko Yoshinaga⁶, Naoko Matsubara⁷, Naomi Sunaga⁸, Ayumi Ito⁷ and Shumpei Yokota⁹, ¹Department of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan, ²Department of Immunology and Infectious Diseases, Aichi Children’s Health and Medical Center, Obu, Japan, ³Department of Allergy and Rheumatology, Chiba Children’s Hospital, Sapporo, Japan, ⁴Hokkaido University, Sapporo, Japan, ⁵Nippon Medical School, Tokyo, Japan, ⁶Evidence solution, Medical Communications, Medical, AbbVie GK, Tokyo, Japan, ⁷Medical, AbbVie GK, Tokyo, Japan, ⁸AbbVie GK, Tokyo, Japan, ⁹Fuji Toranomon Orthopedic Hospital, Gotemba, Japan
Background/Purpose: The safety and efficacy of adalimumab (an anti-TNF-α antibody) treatment in patients with JIA have been demonstrated in clinical trials. This study was conducted…
Abstract Number: 1009 • 2018 ACR/ARHP Annual Meeting
Monocytes Membrane TNF Expression and Anti-TNF Treatment in Rheumatoid Arthritis
Audrey Paoletti¹, Julien Rohmer², Juliette Pascaud³, Bineta Oumouly¹, Elodie Rivière³, Samuel Bitoun⁴, Gaetane Nocturne² and Xavier Mariette⁵, ¹U1184 IMVA, INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, le kremlin bicetre, France, ²INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, ³Immunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre & Fontenay aux Roses, France, ⁴INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, le kremlin bicetre, France, ⁵Rheumatology department, Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique- Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, Paris, France
Background/Purpose: Three monocyte subsets have been described based on their CD14 and CD16 expression profiles. The subpopulation CD14+CD16+ being expanded in rheumatoid arthritis (RA) patient.…
Abstract Number: 2383 • 2018 ACR/ARHP Annual Meeting
Pharmacovigilance of Biologics for Non-Systemic Juvenile Idiopathic Arthritis By the German Biologics Registry
Gerd Horneff¹, Gerd Ganser², Ivan Foeldvari³, Frank Weller-Heinemann⁴, Kirsten Minden⁵ and Ariane Klein⁶, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Klinik für Kinder-und Jugendrheumatologie, Nordwestdeutsches Rheumazentrum, Sendenhorst, Germany, ³Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ⁴Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, ⁵Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁶Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Long-term surveillance of biologics is particularly important in pediatric patients (pts) who may require prolonged treatment. Since 2001, the German Biologics JIA Registry (BIKER)…
Abstract Number: 1174 • 2018 ACR/ARHP Annual Meeting
Comparative Cost per Response for Four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial in Patients with Rheumatoid Arthritis
Jennie H. Best and Jinglan Pei, Genentech, Inc., South San Francisco, CA
Background/Purpose: The cost-effectiveness of different biologic therapies is an important component in guiding treatment decisions for patients with rheumatoid arthritis (RA). The objective of this…
Abstract Number: 2394 • 2018 ACR/ARHP Annual Meeting
Anti-Adalimumab Antibodies Kinetics: An Early Guide for Juvenile Idiopathic Arthritis (JIA) Switching
Juliana Brunelli¹, Clovis A Silva¹, Sandra G Pasoto², Carla GS Saad², Katia T. Kozu¹, Elaine P Leon², Margarete B Vendramini², Nicole Fontoura², Eloisa Bonfa³ and Nadia E Aikawa², ¹Pediatric Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Anti-adalimumab antibody (AAA) production may lead to reduced adalimumab (ADA) serum levels and therapy failure. There are, however, scarce and conflicting data regarding ADA…
Abstract Number: 1192 • 2018 ACR/ARHP Annual Meeting
The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares
Filip van Den Bosch¹, Siegfried Wassenberg², Boulos Haraoui³, Patrick Zueger⁴, Meijing Wu⁴, Ivan Lagunes Galindo⁴ and Andrew Ostor⁵, ¹Ghent University Hospital, Ghent, Belgium, ²Rheumazentrum Ratingen, Ratingen, Germany, ³Université de Montréal, Montreal, QC, Canada, ⁴AbbVie Inc., North Chicago, IL, ⁵Cabrini Medical Center, Melbourne, Australia
Background/Purpose: The AbbVie patient (pt) support program (PSP) is offered to pts prescribed adalimumab for RA and other indications. The purpose of this analysis was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].